Inbred Lewis (LEW/N) female rats develop an arthritis in response to group A streptococcal cell wall peptidoglycan polysaccharide (SCW), which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity, we examined the function of the hypothalamic-pituitary-adrenal (HPA) axis and its ability to modulate the development of the inflammatory response in LEW/N and F344/N rats. We have found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma corticotropin and corticosterone responses to SCW, recombinant human interleukin la, the serotonin agonist quipazine, and synthetic rat/human corticotropin-releasing hormone. LEW/N rats also had smaller adrenal glands and larger thymuses. Replacement doses of dexamethasone decreased the severity of LEW/N rats' SCWinduced arthritis. Conversely, treatment of F344/N rats with the glucocorticoid receptor antagonist RU 486 or the serotonin antagonist LY53857 was associated with development of severe inflammatory disease, including arthritis, in response to SCW. These findings support the concept that susceptibility of LEW/N rats to SCW arthritis is related to defective HPA axis responsiveness to inflammatory and other stress mediators and that resistance of F344/N rats to SCW arthritis is regulated by an intact HPA axis-immune system feedback loop.
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A single intraperitoneal injection of group A streptococcal cell wall fragments (peptidoglycan group-specific polysaccharide; SCW) into euthymic LEW/N female rats induces severe, rapid onset, acute arthritis, followed by a chronic proliferative and erosive arthritis. Athymic LEW.rnu/rnu rats develop the rapid-onset acute-phase arthritis, but the chronic disease is significantly blunted, indicating that the late-, but not the early-, onset disease is thymus dependent. In contrast, histocompatible euthymic and athymic F344 rats develop only minimal, early-onset, swelling of the hind paws that rapidly subsides. These differences in disease pattern and severity are paralleled by the intensity of class II major histocompatibility antigen (Ia) expression in synovial tissues.
The presence of a strain difference in the early-onset, thymic-independent phase of SCW arthritis in athymic LEW.rnu/rnu versus F344.rnu/rnu rats indicates that the thymic-independent phase of arthritis is genetically regulated and that the regulating factor or factors are operative very early in the disease (1) . The mechanisms involved in this regulation are unknown.
Corticosteroids are both potent endogenous anti-inflammatory and immunosuppressive agents and potent endogenous down-regulators of Ia expression (2) (3) (4) . Corticosterone is released early in the course of inflammation, possibly through stimulation of the hypothalamic-pituitary-adrenal (HPA) axis by inflammatory mediators such as endotoxin and interleukin 1 (IL-1) and may be important in maintaining the normal feedback loop between the immune system and the central nervous system (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . We therefore compared the early corticotropin (ACTH) and corticosterone responses to SCW and IL-la in inbred F344/N and LEW/N rats and outbred Harlan-Sprague-Dawley (HSD) rats. Since serotonin (5-HT) is also released during inflammation and down-regulates Ia expression (15) , and since 5-HT pathways represent another route of hypothalamic-pituitary stimulation (16-23), we also compared the effect of the 5-HT agonist quipazine on acute ACTH and corticosterone responses in F344/N, LEW/N, and HSD rats. Furthermore, to evaluate the direct involvement of glucocorticoids in the observed SCW susceptibility of LEW/N rats and SCW resistance of F344/N rats, we examined the ability of replacement doses of glucocorticoids to suppress the SCW susceptibility of the former and the ability of a potent glucocorticoid antagonist RU 486 to reverse the SCW resistance ofthe latter. Data presented here indicate that HPA axis activation is defective in LEW/N rats and that the HPA axis plays a major role in regulating the development of SCW arthritis and probably other inflammatory conditions. MATERIALS AND METHODS Animals. One-hundred-gram, virus antibody-free, female, inbred F344/N and LEW/N rats, and outbred HSD rats, purchased from Harlan-Sprague-Dawley, were acclimatized to 12-hr on/12-hr off light cycles, prior to i.p. injection of various inflammatory mediators.
Drugs and Inflammatory Mediators. SCW was prepared in sterile phosphate-buffered saline (PBS) as described (1) and was injected i.p. at a concentration of 0.02-2 mg of cell wall rhamnose per 5 ml of sterile PBS per 100 g. Recombinant human IL-la (24) was a generous gift from P. Kilian and P. Lomedico (Hoffmann-La Roche). It was injected i.p. at doses ranging from 0.1 to 5 ,g per 0.1 ml of sterile PBS per 100 g. Specific activity ranged from 3 x 108 to 2. 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. bioassay as described (24) . Endotoxin levels in final concentrations injected were <0.0013 EU/100,l. Quipazine was purchased from Sigma. It was injected i.p. at doses ranging from 0.1 to 1 mg per 0.1 ml of sterile water per 100 g. Dexamethasone for cell culture was purchased from Sigma and was used in doses ranging from 0.01 to 100 ,g per ml of sterile normal saline per 100 g. The glucocorticoid receptor antagonist RU 486 (25, ii) was a generous gift from Roussel-UCLAF (Paris). It was suspended in sterile normal saline for i.p. injection at doses ranging from 0.03 to 3 mg per ml per 100 g. The 5-HT antagonist LY53857 [6-methyl-1-(1-methylethyl)ergoline-8-carboxylic acid, 2-hydroxy-1-methylpropyl ester (Z)-2-butenedioate] (26) , was a generous gift from M. Cohen, Lilly Research Laboratories, Eli Lilly. It was injected twice daily i.p. at doses ranging from 0.03 to 0.3 mg per 0.1 ml of sterile water per 100 g. Rat/human corticotropinreleasing hormone (CRH) was purchased from Peninsula Laboratories and was used at doses ranging from 0.01 to 8 ,ug per ml of sterile normal saline per 100 g.
Hormone Assays. Plasma corticosterone was quantitated with a radioimmunoassay (27) kit purchased from Radioassay Systems Laboratories (Carson, CA). ACTH levels were determined by radioimmunoassay as described (28 Fig. 2 shows that while plasma ACTH peaked at 30-60 min postinjection in both F344/N and LEW/N rats, the LEW/N plasma ACTH response to SCW, IL-la, and quipazine was consistently lower than the F344/N response at all time points. Similarly, the LEW/N plasma corticosterone response was lower than the F344/N response at all time points. Total time-integrated plasma ACTH and corticosterone responses to SCW, IL-la, or quipazine were significantly less in LEW/N rats than in F344/N rats ( Table  1 ). In F344/N rats, compared to LEW/N rats, plasma ACTH increased >3-fold as much in response to IL-la, >2-fold as much in response to SCW, and >1.6-fold in response to quipazine. F344/N rats increased plasma corticosterone >2-fold in response to SCW and IL-la, and 1.4-fold in response to quipazine when compared to LEW/N rats. Data represent means ± SEM of total time-integrated plasma ACTH and corticosterone in F344/N and LEW/N rats in response to i.p. SCW (2 mg of cell wall rhamnose per rat), IL-la (1 tg per rat), or quipazine (1 mg per rat). Data were derived by calculation of the area under time course curves shown in Fig. 2 . F/L, ratio of total time-integrated plasma ACTH or corticosterone in F344/N (F) rats versus LEW/N (L) rats.
Pituitary, Adrenal, and Thymus Weights in F344/N Versus LEW/N Rats. Pituitary weights, although not significantly different, were greater in F344/N compared to LEW/N rats ( Table 2) . F344/N adrenal gland weights were slightly but significantly greater than adrenal gland weights from agematched LEW/N rats (P < 0.01). LEW/N thymus weights were significantly higher than F344/N thymus weights (P < 0.01) in age-matched rats.
Effects of Dexamethasone Treatment on LEW/N Rats and of RU 486 or LY53857 on F344/N Rats Treated with SCW. Table   ACTH 3 shows that not only did dexamethasone in the pharmacologic doses totally suppress the arthritis induced by SCW, but physiologic doses (1 ,g daily or 0.5 ,ug twice daily) also significantly suppressed the severity of arthritis as determined by arthritis index compared to SCW plus saline-treated controls (P < 0.05). F344/N 9.6 ± 0.5 (10) 15.6 ± 0.5 (27) 260.0 ± 8.9 (10) LEW/N 8.5 ± 0.4 (13) 13.3 ± 0.7 (26) LEW/N rats were injected with a single dose of SCW (2 mg of cell wall rhamnose per rat), followed by dexamethasone, at the doses indicated, or saline controls. Dexamethasone injections were given once (QD) or twice (b.i.d.) daily for a total of 72 hr, and severity of arthritis (A.I., articular index) was quantitated as described (2) with significant mortality, but it was associated with development of mild to moderate arthritis compared to control rats treated with either agent alone (P < 0.05). Although not all dose variables were explored, the data clearly show that blocking the effects of corticosterone or--5-HT in SCWtreated F344/N rats results in severe or even fatal systemic inflammatory disease.
DISCUSSION
In the experiments reported here, we have shown that acute corticosterone responses to SCW, IL-la, and quipazine are severely depressed in arthritis-susceptible LEW/N rats compared to arthritis-resistant F344/N rats. Outbred HSD rats, which exhibit an intermediate mean susceptibility to SCWinduced arthritis with wide variability (29) , also showed an intermediate mean and wide variability of corticosterone responses to these mediators. Replacement of corticosterone with physiologic doses of dexamethasone significantly suppressed the severity of SCW arthritis in LEW/N rats. Conversely, antagonism of corticosterone in F344/N rats, with the corticosterone receptor antagonist RU 486, was (4, 31) .
The observation that LEW/N rats are deficient in ACTH and corticosterone responses to the 5-HT agonist quipazine, as well as to IL-la and SCW, suggests that the defect in these rats is not solely related to impaired IL-1 stimulation of the HPA axis. The greater LEW/N corticosterone response to quipazine compared to IL-la may result from the multiple pathways through which 5-HT and 5-HT agonists may stimulate the HPA axis since 5-HT is both a major CRH and a potent ACTH secretagogue (16) (17) (18) (19) (20) (21) (22) (23) . The physiologic relevance of such a potential route of 5-HT stimulation of the HPA axis is, however, not clear, since it would be dependent on adequate systemic concentrations of 5-HT released from platelets during inflammation reaching central sites. The importance of 5-HT pathways in intactness of the inflammatory mediator-HPA axis loop and arthritis resistance is also suggested by the development of arthritis in SCW-injected rats treated with the 5-HT2 antagonist LY53857. However, the interpretation of the central effects of LY53857 in induction of arthritis is complicated by the drug's potential local anti-inflammatory activity, which is reflected in the lower mortality of the LY53857 plus SCW-treated animals compared to the RU 486 plus SCW-treated animals.
The data presented here, coupled with the markedly enhanced inflammatory disease in SCW-injected F344/N rats following pharmacologic interruption of the HPA axis, and suppression of arthritis severity in SCW-injected LEW/N rats following replacement doses of dexamethasone, provide strong evidence that arthritis susceptibility in the LEW/N rat, and resistance in the F344/N rat, is regulated, at least partially, through corticosterone production and HPA axis responsiveness to inflammatory and possibly other stress mediators. LEW/N rats, therefore, represent a unique animal model for a genetically determined defect in the central nervous systeminflammatory/immune system feedback loop (i.e., the stress response). Whether of hypothalamic or pituitary origin, this defect is associated with increased susceptibility to arthritis in response to SCW, and could also contribute to the increased susceptibility to other experimentally induced inflammatory diseases observed in LEW/N rats (32) (33) (34) (35) (36) (37) (38) (39) .
The data may also have implications for susceptibility to rheumatoid arthritis in humans. Our data raise the possibility that susceptibility to rheumatoid arthritis may be related to defective HPA axis production of stress hormones in response to inflammatory and possibly other stress mediators. Therefore, evaluation of these responses in patients with rheumatoid arthritis may provide new insights into the pathogenesis of rheumatoid arthritis and other inflammatory/ autoimmune diseases.
